Brain Imaging Biomarkers in Patients With Brain Metastasis
Imaging Trial of Biomarkers to Guide Individualized Therapy in Patients With Brain Metastasis Receiving Radiotherapy
University Health Network, Toronto
90 participants
Oct 5, 2021
INTERVENTIONAL
Conditions
Summary
A biomarker is a measurable indicator of the severity or presence of some disease state. In this study, brain metastases patients who will be receiving radiation treatment, will undergo CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans prior to and after radiation treatment to measure these biomarkers. This is a single-center phase II study to validate the predictive abilities of biomarkers, in terms of determining how patients will respond to radiation treatment.
Eligibility
Inclusion Criteria5
- Biopsy proven primary malignancy (original biopsy is adequate as long as the brain imaging is consistent with brain metastases)
- At least one index lesion with diameter \> 1cm and without imaging evidence of hemorrhage
- Patients age \> 18 years of age
- Patients planned for RT to brain metastases
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria3
- Previous Whole Brain Radiotherapy
- Previous radiosurgery to the index lesion
- Individuals unable to undergo contrasted MRI for whatever reason
Interventions
CT and MRI scans will occur before and after radiation therapy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04197297